Compound, pharmaceutical composition, use of a compound, methods for treating a hpparso-mediated disease or condition, to lower triglycerides in a patient, to treat type 2 diabetes, to decrease insulin resistance or to lower blood pressure in a patient , to decrease the fribogen levels in a patient, to decrease the ldlc in a patient and to change the particle size of the small dense ldl to normal dense ldl in a patient, and, use of an hpparso agonist

摘要

"COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, METHODS FOR TREATING A DISEASE OR CONDITION MEDIATED BY HPPARSo, TO REDUCE TRIGLYCERIDES IN A PATIENT, TO TREAT TYPE 2 DIABETES, REDUCING RESISTANCE IN HEALING IN HEALING PATIENT, TO REDUCE FRIBOGEN LEVELS IN A PATIENT, TO REDUCE LDLC IN A PATIENT AND TO CHANGE THE PARTICLE SIZE FROM SMALL DENSE TO NORMAL DENSE IN A PATIENT, AND, USE OF AN HPPAROUS AGONIST ". Compounds of Formula (1) are disclosed. These compounds include selective activators of the human PPAR delta.